Beacon Biosignals announced that it extended its Series B financing to bring the round to $97 million.
In November 2025, the Boston-based company announced that it raised $86 million in its oversubscribed Series B round. With the extension, the company says its cumulative financing now totals more than $132 million.
Related: neuroClues closes €10M Series A, bringing total funding to €25M
New investors JSL Health, Palo Santo VC, Kicker Ventures and Samsung Next contributed to the extension. A syndicate of healthcare and technology investors, including Innoviva, Google Ventures, Nexus NeuroTech Ventures, S32, Catalio Capital Management and Takeda led the initial Series B. General Catalyst, Logos Capital, Casdin Capital and Indicator Ventures participated, too.
Beacon said it expects the new capital to further accelerate its mission to transform brain health through scalable, at-home EEG and advanced analytics.
The company develops the Waveband device (previously called the Dreem 3S), which it designed to directly measure brain activity during both sleep and wakefulness. The company says the wearable headband brings gold-standard neurophysiology out of the lab and into patients’ homes. Biosignal data produced by the device provides valid, longitudinal measures of brain function across diverse populations.
The company’s platform received FDA clearance in September 2023, then got clearance for updated algorithms in late 2024.
“This milestone reflects strong momentum behind our vision to make brain health measurable, scalable, and actionable,” said Jacob Donoghue, CEO of Beacon Biosignals. “We’re grateful for the support of our new and existing investors as we build the future of brain health.”
